雷珠单抗治疗年龄相关性黄斑变性继发视网膜色素上皮撕裂的前瞻性研究
这项前瞻性单臂多中心研究纳入24只年龄相关性黄斑变性继发视网膜色素上皮撕裂眼,每月玻璃体腔注射0.5mg雷珠单抗持续12个月。平均最佳矫正视力从基线50.3个ETDRS字母稳定至52.9个字母(P=0.39),平均中央视网膜厚度从571µm降至436µm(P=0.0001)。结论为每月雷珠单抗治疗可使视力在12个月内保持稳定。
要点
- 每月雷珠单抗0.5mg治疗12个月,平均视力保持稳定(P=0.39)。
- 平均中央视网膜厚度从571µm显著降至436µm(P=0.0001)。
- 仅1眼(4%)视力下降≥15字母,2眼(8%)视力提升≥15字母。
核心结论
- 在年龄相关性黄斑变性继发视网膜色素上皮撕裂眼中,每月玻璃体腔注射雷珠单抗治疗12个月可使视力保持稳定。
研究设计与样本
- RIP研究为前瞻性、单臂、多中心、研究者发起的临床试验,纳入24例患者24只眼,每月玻璃体腔注射0.5mg雷珠单抗持续12个月,每月评估形态学与功能学指标。
主要发现
- 平均最佳矫正视力从基线50.3个ETDRS字母(±18.7;Snellen等效20/100)至末次访视52.9个字母(±19.7;Snellen等效20/100),P=0.39。
- 1只眼(4%)视力下降≥15个字母,2只眼(8%)视力提升≥15个字母。
- 平均中央视网膜厚度从571µm(±185µm)降至436µm(±171µm),P=0.0001。
- 视功能相关生活质量保持稳定,平均VFQ-25评分从基线79.0(±10.8)至末次访视74.3(±13.9),P=0.12。
临床怎么用
- 对于年龄相关性黄斑变性继发视网膜色素上皮撕裂眼,可考虑每月玻璃体腔注射0.5mg雷珠单抗治疗以稳定视力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess efficacy of intravitreal ranibizumab in retinal pigment epithelium tears secondary to neovascular age-related macular degeneration. METHODS: The Ranibizumab In Pigment epithelial tears secondary to age-related macular degeneration (RIP) study is a prospective, single-arm, multicenter, investigator-initiated trial. Twenty four eyes of 24 patients with a retinal pigment epithelium tear secondary to age-related macular degeneration received monthly intravitreal injection of 0.5mg ranibizumab for 12 months, together with monthly assessments of morphologic and functional efficacy parameters. Primary outcome measure was mean best-corrected visual acuity at final visit compared with baseline. RESULTS: Mean best-corrected visual acuity remained stable over the 12-month study period with 50.3 Early Treatment of Diabetic Retinopathy Study letters (±18.7; Snellen equivalent 20/100) at baseline and 52.9 letters (±19.7; Snellen equivalent 20/100) at final visit (P = 0.39). One eye (4%) experienced a vision loss of ≥15 letters, and 2 eyes (8%) gained ≥15 letters. Mean central retinal thickness decreased from 571 µm (±185 µm) to 436 µm (±171 µm; P = 0.0001). Vision-related quality of life was stable with a mean VFQ-25 score of 79.0 (±10.8) at baseline and 74.3 (±13.9) at final visit (P = 0.12). CONCLUSION: In retinal pigment epithelium tears secondary to age-related macular degeneration, monthly intravitreal ranibizumab therapy results in stabilization of visual acuity over 12 months.
引用
- Larsen PP, Oishi A, Bedar MS, et al. RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective Study. Retina. 2019. PMID: 30198967. doi:10.1097/IAE.0000000000002311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。